The effects of the 5-HT7 receptor on hippocampal long-term potentiation and apoptosis in a rat model of Alzheimer’s disease

Pharmacological Mechanisms Underlying the Neuroprotective Effects of Alpinia oxyphylla Miq. on Alzheimer’s Disease

“…It also regulates the rapid influx of sodium (Na + ) and Ca 2+ , leading to the subsequent cellular depolarization by cAMP (hsa04024), MAPK (hsa04010), and phosphoinositide 3-kinase (PI3K)/AKT (hsa04151) signaling pathways. For monoamine neurotransmitters, serotonin (5-hydroxytryptamine, 5-HT) binds to ionotropic 5-HT3 receptors, GPCR 5-HT receptors, 5-HT1 (Gi/Go -coupled), 5-HT2 (Gq-coupled), 5-HT4/6/7 (Gs-coupled), and 5-HT5 receptors, which can be directly or indirectly involved in the regulation of synaptic transmission, neuronal excitability, synaptic plasticity, and neuroprotection [55,56]. Therefore, we hypothesize that A. oxyphylla or terpenoids are natural compounds that may play an important role in mediating anti-AD effects by functional annotation and enrichment analysis of neurotransmitter receptors.…”

The serotonergic system in Alzheimer's Disease

“…The 5-HT7 receptors, which are widely distributed in the hippocampus are one of the newly identified types of the 5-HT receptor family. (Nikiforuk, 2015;Hashemi-Firouzi et al, 2017) Also, the 5-HT7 receptors are located in the dorsal raphe nucleus, thalamus, hypothalamus and frontal cortex. (Kusek et al, 2015) As stated by Hashemi-Firouzi et al, the 5-HT7 receptors are associated with behavioral disorders such as depression, memory, anxiety, learning, and other hippocampal functions.…”

“…(Kusek et al, 2015) As stated by Hashemi-Firouzi et al, the 5-HT7 receptors are associated with behavioral disorders such as depression, memory, anxiety, learning, and other hippocampal functions. (Hashemi-Firouzi et al, 2017) Additionally, Nikiforuk et al mentioned that the 5-HT7 receptors both have a physiological role in the regulation of the central nervous (CNS) system and a potential therapeutic role in treating CNS disorders. (Nikiforuk, 2015) In this context, Hashemi-Firouzi et al have summarized ligands of the 5-HT7 receptors in CNS disorders and the present data about the effects of the ligands in animal models as models of central nervous system (CNS) disorders.…”

“…(Nikiforuk, 2015) In this context, Hashemi-Firouzi et al have summarized ligands of the 5-HT7 receptors in CNS disorders and the present data about the effects of the ligands in animal models as models of central nervous system (CNS) disorders. (Hashemi-Firouzi et al, 2017) However, they suggest further studies to widen information about the 5-HT7 receptors and therapeutic potential of their ligands. (Hashemi-Firouzi et al, 2017) Kusek et al have determined that the inhibition of the 5-HT7 receptors increases both release and metabolism of 5-HT in the prefrontal cortex.…”

“…(Hashemi-Firouzi et al, 2017) However, they suggest further studies to widen information about the 5-HT7 receptors and therapeutic potential of their ligands. (Hashemi-Firouzi et al, 2017) Kusek et al have determined that the inhibition of the 5-HT7 receptors increases both release and metabolism of 5-HT in the prefrontal cortex. (Kusek et al, 2015) Additionally, blockade of the 5-HT7 receptors is thought to be beneficial against schizophrenia-like cognitive disorders; the 5-HT7 receptors might have role in the treatment of depression.…”